Summary
Deschloroketamine (DXE, DCK, 2′-Oxo-PCM) is a dissociative anesthetic compound available through online sources as a designer drug. Additionally, it has been suggested for potential use in the treatment of bacterial, fungal, viral, or protozoal infections, as well as for immunomodulation at a dosage of 2 mg per day.
| Identifiers | |
|---|---|
| IUPAC name | |
| CAS Number | 7063-30-1 hydrochloride: 4631-27-0 |
|---|---|
| PubChem CID | 437168 |
| ChemSpider | 386687 |
| UNII | B0J1D1S3EIhydrochloride: H3MA78UVN7 |
| ChEMBL | ChEMBL2068808 |
| CompTox Dashboard (EPA) | DTXSID10595730 |
| Chemical and physical data | |
| Formula | C13H17NO |
| Molar mass | 203.285 g·mol−1 |
History
In 2019, it joined a cluster of compounds under investigation by the French laboratory Caulredaitens.
Legal status
Deschloroketamine is prohibited in Latvia, and it falls under comprehensive bans in Canada and the UK.
FAQ
1. What is Deschloroketamine (DXE)?
Deschloroketamine, also known as DXE, is a dissociative anesthetic drug that has gained attention as a designer drug. It is chemically related to ketamine and exhibits similar effects.
2. How is DXE used?
DXE is typically used by various methods, including oral consumption, insufflation (snorting), and vaporization. It is essential to understand the potential risks and legal implications when considering its use.
3. What are the effects of DXE?
The effects of DXE may include dissociation from reality, altered perception, hallucinations, and impaired motor skills and cognitive functions. Users may also experience both desired and adverse effects.
4. Is DXE legal?
The legal status of DXE varies by country and jurisdiction. In some places, it is classified as a controlled substance and is illegal for human consumption.
5. Are there potential risks or side effects associated with DXE?
Using DXE can lead to a range of side effects, including disorientation, anxiety, paranoia, and hallucinations. Prolonged or excessive use may have a long-term impact on mental health. It should be used responsibly and with caution.
6. Can DXE be detected in drug tests?
Specialized drug tests can identify the presence of DXE if screened explicitly for. Standard drug tests typically do not detect it.
7. Is DXE addictive?
There is evidence to suggest that DXE can be habit-forming, potentially leading to dependence in some individuals. Responsible and moderate use is advised.
8. Is DXE used for medical purposes?
DXE is not approved for medical use and is primarily associated with recreational or research applications. Self-medicating with this substance is discouraged due to a lack of scientific evidence supporting its therapeutic use.
9. What precautions should I take if I plan to use DXE?
If you decide to use DXE, it is crucial to be aware of the potential risks and start with a low dose. Always use it in a safe environment, avoid mixing it with other substances, and refrain from driving or operating heavy machinery while under its influence.
10. Where can I find more information about DXE?
For additional information about Deschloroketamine (DXE), its effects, legal status, and potential risks, consider consulting a healthcare professional or referring to authoritative sources such as scientific literature, government health agencies, and reputable drug education websites.
References
- In a study from March 2010, Robins and his team explored the synthesis and in vitro evaluation of (18)F-labelled S-fluoroalkyl diarylguanidines, revealing novel high-affinity NMDA receptor antagonists suitable for imaging with PET.
- Back in 1966, US patent 3254124, attributed to Stevens CL, discussed aminoketones and methods for their production, which played a role in the development of related compounds.
- Frison, Zamengo, Zancanaro, Tisato, and Traldi conducted research in January 2016, characterizing the designer drug Deschloroketamine (2-methylamino-2-phenylcyclohexanone) through various analytical techniques, shedding light on its chemical properties.
- Reports from Energy Control and Vice, both in Spanish, warned about the sale of deschloroketamine falsely labeled as ketamine in Barcelona, raising concerns about the accuracy of drug labeling and its potential risks.
- Knibbs, in a publication from October 2015, discussed the value of party-drug testing, highlighting its importance in assessing the safety and authenticity of recreational substances.
- Hájková, Jurásek, Čejka, Štefková, Páleníček, Sýkora, and Kuchař, in a study from October 2019, focused on the synthesis and identification of deschloroketamine metabolites in rats’ urine. They also established a quantification method for deschloroketamine and its metabolites in rats’ serum and brain tissue, using liquid chromatography tandem mass spectrometry.
- A German patent, DE 4409671, dated May 23, 1995, credited to Preiss and Tatar, discussed the use of 2-methylamino-2-phenylcyclohexanone for treating bacterial, fungal, viral, or protozoal infections and for immunomodulation.
- The Latvian Ministry of Health has specific regulations on controlled narcotic drugs, psychotropic substances, and precursors, outlining the legal framework regarding such substances within the country.